Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 300
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, kinase protein assay kits, and stable cell lines, as well as biotinylated kinases to use in the study of kinase-molecule interactions. The company also offers profiling, NanoBRET TE intracellular kinase...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell